ArticleBMC infectious diseases2026
Clinical distribution and drug resistance of carbapenem-resistant Pseudomonas aeruginosa infection in Eastern China from 2019 to 2024.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study aimed to analyze the clinical distribution and changes in drug resistance of Pseudomonas aeruginosa (PA) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) at The Affiliated Suzhou Hospital of Nanjing Medical University from 2019 to 2024, providing evidence for hospital infection prevention and control, as well as the rational clinical use of antibiotics.
methodsA six-year retrospective study was conducted. Non-duplicate PA strains isolated from clinical specimens in this hospital from January 1, 2019, to December 31, 2024, were included. Statistical analysis was performed on specimen sources, department distribution, patient epidemiological characteristics, and antimicrobial susceptibility test results.
resultsA total of 4,046 PA strains were detected, of which 1,340 were CRPA, resulting in an overall detection rate of 33.12%. The CRPA detection rate showed minor fluctuations from 2019 to 2023, with a peak of 37.17% in 2022, and then decreased to 26.22% in 2024. CRPA was primarily isolated from sputum (54.48%) and bronchoalveolar lavage fluid (13.96%), and was predominantly distributed in the Intensive Care Unit (ICU, 39.70%), Emergency Department (18.13%), and Respiratory Department (10.82%). The majority of CRPA cases (85.37%) occurred in patients aged over 60 years, a proportion significantly higher than that in the non-CRPA group (79.38%) (χ² = 26.210, P < 0.001). Among the CRPA, resistance rates to imipenem and meropenem remained high, at 97.09% and 77.54%, respectively, with no significant decrease observed over the six-year period. The resistance rate to amikacin was the lowest (24.18%) and showed a continuous declining trend (P < 0.001).
conclusionFrom 2019 to 2024, the CRPA detection rate in this hospital remained high, indicating a serious drug resistance situation, particularly concentrated in the ICU and among the elderly population. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.